98556-65-1 Usage
General Description
3-Cyano-5-nitrobenzoic acid is a chemical compound with a molecular formula of C8H4N2O4. It is a yellow crystalline solid with a molecular weight of 188.13 g/mol. 3-CYANO-5-NITROBENZOIC ACID is a derivative of benzoic acid and contains both a cyano group and a nitro group, making it a useful building block for the synthesis of various organic compounds. 3-Cyano-5-nitrobenzoic acid is commonly used in the manufacturing of pharmaceuticals, dyes, and other organic chemicals. It is also used as a reagent in organic synthesis and as an intermediate in the production of agrochemicals. Additionally, this compound has potential applications in the field of materials science and can be used as a precursor for the preparation of various functional materials.
Check Digit Verification of cas no
The CAS Registry Mumber 98556-65-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,8,5,5 and 6 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 98556-65:
(7*9)+(6*8)+(5*5)+(4*5)+(3*6)+(2*6)+(1*5)=191
191 % 10 = 1
So 98556-65-1 is a valid CAS Registry Number.
98556-65-1Relevant articles and documents
INSECTICIDAL COMPOUNDS
-
Page/Page column 37, (2008/12/07)
A compound of formula (I), wherein A1, A2, A3, A4, R1, R2, R3, G1, G2, G3 and Q are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control insect, acarine, mollusc and nematode pests.
Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
-
, (2008/06/13)
The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.